The Open Targets Blog

MAY 9, 2024

In December 2023, we introduced the pharmacogenetics widget in the Open Targets Platform, which brings in data from PharmGKB on the influence of genetic variation on drug responses. Pharmacogenetics examines the link between genetics and drug response, helping in the prioritisation of drug targets that minimise the risk of adverse effects.

Pharmacogenetics 72

Pharmacogenetics Drugs Therapies Disease 72

ASPET

SEPTEMBER 16, 2024

Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. Elimusertib, a novel ATR kinase inhibitor, can prevent repair of damaged DNA, increasing efficacy of DNA damaging cytotoxic therapies. Subsequent activation of DNA damage response (DDR) pathways can induce resistance.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

AUGUST 4, 2023

131 I-mIBG has emerged as a promising therapy for high-risk NB and kills tumor cells by radiation. PMAT is expressed intracellularly in neuroblastoma cells, transports mIBG and thus could impact tumor retention and response to 131 I-mIBG therapy. Neuroblastoma (NB) is a pediatric cancer with low survival rates in high-risk patients.

Pharmacogenetics 100

Pharmacogenetics Therapies Disease 100

ASPET

OCTOBER 12, 2023

With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB). Achieving adequate exposure of a therapeutic agent at the target is a critical determinant of efficacious chemotherapy.

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. Ataxia telangiectasia mutated (ATM) kinase is a key regulator of DSB repair, and ATM inhibitors are being explored as radiosensitizers for various tumors, including primary and metastatic brain tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). Two global pharmaceutical clients are also piloting the technology. We need to urgently address these with a better model.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40